A Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in Patients With Metastatic Malignant Melanoma.
Phase of Trial: Phase II
Latest Information Update: 10 May 2018
At a glance
- Drugs Docetaxel (Primary) ; Sargramostim (Primary) ; Vinorelbine (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 15 Aug 2011 Planned end date changed from Jan 2011 to Jan 2012 as reported by ClinicalTrials.gov.
- 18 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Mar 2010 Planned end date changed from Dec 2009 to Jan 2011 as reported by ClinicalTrials.gov.